Recently Added Drugs
1. Aspruzyo Sprinkle patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12161761 | SPIL | Extended release multiparticulates of ranolazine |
Jan, 2038
(12 years from now) | |
Drugs and Companies using RANOLAZINE ingredient
Market Authorisation Date: 28 February, 2022
Treatment: NA
Dosage: GRANULES, EXTENDED RELEASE
More Information on Dosage
ASPRUZYO SPRINKLE family patents
2. Atorvaliq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12168069 | CMP DEV LLC | Aqueous suspension suitable for oral administration |
Jun, 2037
(12 years from now) | |
Drugs and Companies using ATORVASTATIN CALCIUM ingredient
Market Authorisation Date: 01 February, 2023
Treatment: NA
Dosage: SUSPENSION
More Information on Dosage
ATORVALIQ family patents
3. Attruby patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9642838 | BRIDGEBIO PHARMA | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
May, 2031
(6 years from now) | |
| US10513497 | BRIDGEBIO PHARMA | Process for preparing AG-10, its intermediates, and salts thereof |
Feb, 2038
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10398681 | BRIDGEBIO PHARMA | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
May, 2031
(6 years from now) | |
| US10842777 | BRIDGEBIO PHARMA | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
May, 2031
(6 years from now) | |
| US8877795 | BRIDGEBIO PHARMA | Identification of stabilizers of multimeric proteins |
May, 2031
(6 years from now) | |
| US9169214 | BRIDGEBIO PHARMA | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
May, 2031
(6 years from now) | |
| US9913826 | BRIDGEBIO PHARMA | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
Mar, 2033
(8 years from now) | |
| US11919865 | BRIDGEBIO PHARMA | Processes for preparing AG-10, its intermediates, and salts thereof |
Feb, 2038
(13 years from now) | |
| US11058668 | BRIDGEBIO PHARMA | Methods of treating TTR amyloidosis using AG10 |
Mar, 2039
(14 years from now) | |
| US12070449 | BRIDGEBIO PHARMA | Methods of treating TTR amyloidosis using AG10 |
Mar, 2039
(14 years from now) | |
| US11260047 | BRIDGEBIO PHARMA | Formulations of AG10 |
Aug, 2039
(14 years from now) | |
| US12005043 | BRIDGEBIO PHARMA | Formulations of AG10 |
Aug, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 22, 2029 |
Drugs and Companies using ACORAMIDIS HYDROCHLORIDE ingredient
NCE-1 date: 22 November, 2028
Market Authorisation Date: 22 November, 2024
Treatment: Treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (attr-cm)
Dosage: TABLET
More Information on Dosage
ATTRUBY family patents
4. Auvelity patent expiration
Can you believe AUVELITY received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12156914 | AXSOME | Pharmaceutical compositions comprising bupropion and cysteine |
Jan, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 18, 2025 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient
Market Authorisation Date: 18 August, 2022
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of AUVELITY before it's drug patent expiration?
More Information on Dosage
AUVELITY family patents
5. Bromsite patent expiration
Can you believe BROMSITE received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE50218 | SUN PHARM | Non-steroidal anti-inflammatory ophthalmic compositions |
Mar, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 08, 2019 |
Drugs and Companies using BROMFENAC SODIUM ingredient
Market Authorisation Date: 08 April, 2016
Treatment: Treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery
Dosage: SOLUTION/DROPS
How can I launch a generic of BROMSITE before it's drug patent expiration?
More Information on Dosage
BROMSITE family patents
6. Cabenuva Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE50189 | VIIV HLTHCARE | NA |
Nov, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-184) | Jan 31, 2025 |
| New Patient Population(NPP) | Mar 29, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
CABENUVA KIT family patents
7. Crexont patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12178918 | IMPAX | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Oct, 2034
(9 years from now) | |
| US12178919 | IMPAX | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof |
Oct, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 07, 2027 |
Drugs and Companies using CARBIDOPA; LEVODOPA ingredient
Market Authorisation Date: 07 August, 2024
Treatment: Treatment of parkinson's disease
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
CREXONT family patents
8. Definity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12161730 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
Drugs and Companies using PERFLUTREN ingredient
Market Authorisation Date: 31 July, 2001
Treatment: Method of using the drug substance/drug product for ultrasound imaging
Dosage: INJECTABLE
More Information on Dosage
DEFINITY family patents
9. Definity Rt patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12161730 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(12 years from now) | |
Drugs and Companies using PERFLUTREN ingredient
Market Authorisation Date: 31 July, 2001
Treatment: Method of using the drug substance/drug product for ultrasound imaging
Dosage: INJECTABLE
More Information on Dosage
DEFINITY RT family patents
10. Dextenza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12150896 | OCULAR THERAPEUTIX | Punctal plug and bioadhesives |
Oct, 2036
(11 years from now) | |
| US12144889 | OCULAR THERAPEUTIX | Methods of treating allergic conjunctivitis |
Apr, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 30, 2021 |
| New Indication(I-800) | Jun 20, 2022 |
| New Indication(I-876) | Oct 07, 2024 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 30 November, 2018
Treatment: Treatment of ocular inflammation and pain following ophthalmic surgery; Treatment of ocular itching associated with allergic conjunctivitis
Dosage: INSERT
More Information on Dosage
DEXTENZA family patents
11. Epsolay patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12156946 | GALDERMA LABS LP | Method for preparing particles comprising metal oxide coating and particles with metal oxide coating |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 22, 2025 |
Drugs and Companies using BENZOYL PEROXIDE ingredient
Market Authorisation Date: 22 April, 2022
Treatment: NA
Dosage: CREAM
More Information on Dosage
EPSOLAY family patents
12. Invokamet patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8222219 (Pediatric) | JANSSEN PHARMS | Glucopyranoside compound |
Oct, 2025
(8 months from now) | |
|
US7943788 (Pediatric) | JANSSEN PHARMS | Glucopyranoside compound |
Jan, 2028
(2 years from now) | |
|
US8513202 (Pediatric) | JANSSEN PHARMS | Crystalline form of 1-(beta-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Jun, 2028
(3 years from now) | |
|
US7943582 (Pediatric) | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Aug, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-735) | May 20, 2019 |
| M(M-197) | Feb 01, 2020 |
| New Indication(I-788) | Oct 29, 2021 |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 29 March, 2017
Market Authorisation Date: 08 August, 2014
Treatment: NA
Dosage: TABLET
How can I launch a generic of INVOKAMET before it's drug patent expiration?
More Information on Dosage
INVOKAMET family patents
13. Invokamet Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8222219 (Pediatric) | JANSSEN PHARMS | Glucopyranoside compound |
Oct, 2025
(8 months from now) | |
|
US7943788 (Pediatric) | JANSSEN PHARMS | Glucopyranoside compound |
Jan, 2028
(2 years from now) | |
|
US8513202 (Pediatric) | JANSSEN PHARMS | Crystalline form of 1-(beta-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Jun, 2028
(3 years from now) | |
|
US7943582 (Pediatric) | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Aug, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-735) | May 20, 2019 |
| New Indication(I-788) | Oct 29, 2021 |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 29 March, 2017
Market Authorisation Date: 20 September, 2016
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of INVOKAMET XR before it's drug patent expiration?
More Information on Dosage
INVOKAMET XR family patents
14. Invokana patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8222219 (Pediatric) | JANSSEN PHARMS | Glucopyranoside compound |
Oct, 2025
(8 months from now) | |
|
US7943788 (Pediatric) | JANSSEN PHARMS | Glucopyranoside compound |
Jan, 2028
(2 years from now) | |
|
US8513202 (Pediatric) | JANSSEN PHARMS | Crystalline form of 1-(beta-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate |
Jun, 2028
(3 years from now) | |
|
US7943582 (Pediatric) | JANSSEN PHARMS | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate |
Aug, 2029
(4 years from now) | |
|
US10617668 (Pediatric) | JANSSEN PHARMS | Pharmaceutical formulations |
Nov, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-733) | May 20, 2019 |
| M(M-197) | Feb 01, 2020 |
| New Indication(I-788) | Oct 29, 2021 |
| New Indication(I-809) | Sep 27, 2022 |
Drugs and Companies using CANAGLIFLOZIN ingredient
NCE-1 date: 29 March, 2017
Market Authorisation Date: 29 March, 2013
Treatment: NA
Dosage: TABLET
How can I launch a generic of INVOKANA before it's drug patent expiration?
More Information on Dosage
INVOKANA family patents
15. Lutathera patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12168063 | AAA USA INC | Stable, concentrated radionuclide complex solutions |
Jul, 2038
(13 years from now) | |
|
US12161732 (Pediatric) | AAA USA INC | Stable, concentrated radionuclide complex solutions |
Jan, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 26, 2023 |
| Orphan Drug Exclusivity(ODE-166) | Jan 26, 2025 |
| New Patient Population(NPP) | Apr 23, 2027 |
| Orphan Drug Exclusivity(ODE-479) | Apr 23, 2031 |
| Pediatric Exclusivity(PED) | Oct 23, 2031 |
Drugs and Companies using LUTETIUM LU 177 DOTATATE ingredient
NCE-1 date: 23 October, 2030
Market Authorisation Date: 26 January, 2018
Treatment: Treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (gep-nets), including foregut, midgut, and hindgut neuroen...
Dosage: SOLUTION
More Information on Dosage
LUTATHERA family patents
16. Minocin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12161656 | REMPEX | Tetracycline compositions |
May, 2031
(6 years from now) | |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 01 January, 1982
Treatment: NA
Dosage: INJECTABLE
How can I launch a generic of MINOCIN before it's drug patent expiration?
More Information on Dosage
MINOCIN family patents
17. Ontralfy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12042484 | FIDELITY BIOPHARMA | Tizanidine liquid preparation and use thereof |
May, 2042
(17 years from now) | |
Drugs and Companies using TIZANIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 12 December, 2024
Treatment: Treatment of spasticity
Dosage: SOLUTION
More Information on Dosage
ONTRALFY family patents
18. Pylarify patent expiration
Can you believe PYLARIFY received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12070513 | PROGENICS PHARMS INC | PSMA-binding agents and uses thereof |
Jul, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 26, 2026 |
Drugs and Companies using PIFLUFOLASTAT F-18 ingredient
NCE-1 date: 26 May, 2025
Market Authorisation Date: 26 May, 2021
Treatment: Method of positron emission tomography (pet) in men with prostate cancer
Dosage: SOLUTION
More Information on Dosage
PYLARIFY family patents
19. Raldesy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8133893 | KAMAT | Trazodone and trazodone hydrochloride in purified form |
Mar, 2029
(4 years from now) | |
Drugs and Companies using TRAZODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 26 November, 2024
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
RALDESY family patents
20. Revuforj patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10683302 | SYNDAX | Inhibitors of the menin-MLL interaction |
Jun, 2037
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11479557 | SYNDAX | Inhibitors of the menin-MLL interaction |
Jun, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2029 |
| Orphan Drug Exclusivity(ODE-502) | Nov 15, 2031 |
Drugs and Companies using REVUMENIB CITRATE ingredient
NCE-1 date: 15 November, 2028
Market Authorisation Date: 15 November, 2024
Treatment: Treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2a gene (kmt2a) translocation in adult and pediatric patients 1 year and older
Dosage: TABLET
More Information on Dosage
REVUFORJ family patents
21. Rybelsus patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11833248 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Feb, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 20, 2022 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| M(M-252) | Jan 16, 2023 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 09 December, 2024
Treatment: Method of treating type 2 diabetes mellitus
Dosage: TABLET
More Information on Dosage
RYBELSUS family patents
22. Twyneo patent expiration
Can you believe TWYNEO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12156946 | GALDERMA LABS LP | Method for preparing particles comprising metal oxide coating and particles with metal oxide coating |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jul 26, 2024 |
Drugs and Companies using BENZOYL PEROXIDE; TRETINOIN ingredient
Market Authorisation Date: 26 July, 2021
Treatment: NA
Dosage: CREAM
More Information on Dosage
TWYNEO family patents
23. Vabomere patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12171772 | REMPEX | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 29, 2022 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 29, 2027 |
Drugs and Companies using MEROPENEM; VABORBACTAM ingredient
NCE-1 date: 29 August, 2026
Market Authorisation Date: 29 August, 2017
Treatment: NA
Dosage: POWDER
More Information on Dosage
VABOMERE family patents
24. Velsipity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12156866 | PFIZER | Methods of treating conditions related to the S1P1 receptor |
Jan, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2028 |
Drugs and Companies using ETRASIMOD ARGININE ingredient
NCE-1 date: 13 October, 2027
Market Authorisation Date: 12 October, 2023
Treatment: A method for treating ulcerative colitis by administering a therapeutically effective amount of estrasimod arginine as claimed
Dosage: TABLET
More Information on Dosage
VELSIPITY family patents
25. Xywav patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12138233 | JAZZ | Methods of treating idiopathic hypersomnia |
Feb, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 21, 2023 |
| New Indication(I-870) | Aug 12, 2024 |
| Orphan Drug Exclusivity(ODE-231) | Jul 21, 2027 |
| Orphan Drug Exclusivity(ODE-361) | Jul 21, 2027 |
| Pediatric Exclusivity(PED) | Jan 21, 2028 |
| Orphan Drug Exclusivity(ODE-369) | Aug 12, 2028 |
Market Authorisation Date: 21 July, 2020
Treatment: Treatment of idiopathic hypersomnia with a mixture of sodium, potassium, magnesium, and calcium salts of ghb
Dosage: SOLUTION
How can I launch a generic of XYWAV before it's drug patent expiration?
More Information on Dosage
XYWAV family patents